Welcome to GTx.

GTx is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting, and other serious medical conditions.

To learn more, we invite you to explore our site.

 

GTx Appoints Kenneth S Robinson, MD to the Board of Directors

GTx, Inc. Announces First Quarter 2008 Financial Results Conference Call and Webcast

First Fracture Prevention Study in Men Receiving ADT for Prostate Cancer Presented at AACR Annual Meeting
GTx Announces Upcoming Presentation of Toremifene Citrate 80 mg Phase III ADT Clinical Trial Results